Page last updated: 2024-08-21

fluorobenzenes and Atherogenesis

fluorobenzenes has been researched along with Atherogenesis in 98 studies

Research

Studies (98)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	38 (38.78)	29.6817
2010's	58 (59.18)	24.3611
2020's	2 (2.04)	2.80

Authors

Authors	Studies
Bots, ML; Chen, Y; Fu, L; Hu, B; Hu, H; Karlson, BW; Li, H; Li, X; Li, Z; Meng, X; Nie, Z; Wang, Y; Wei, D; Zhao, B; Zheng, H	1
Bots, ML; Chen, Y; Fu, L; Hu, B; Hu, H; Karlson, BW; Li, H; Li, X; Li, Z; Nie, Z; Qin, Y; Wang, A; Wang, Y; Wei, D; Zhao, B; Zheng, H	1
Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M	3
Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK	1
Elisaf, M; Kei, A; Liberopoulos, E; Rizzo, M; Tellis, K; Tselepis, A	1
Alshehri, MM; Alzoman, NZ; Darwish, IA; Maher, HM; Sultan, MA; Wani, TA	1
Chi, JF; Guo, HY; Ji, Z; Liu, LB; Lv, HT; Shi, YF; Tang, WL; Xu, FK	1
Boudoulas, H; Chalikias, G; Kapelouzou, A; Karayannakos, P; Konstantinides, S; Kostakis, A; Schäfer, K; Tentes, I; Tziakas, D	1
Cai, S; Chu, X; Li, Y; Liu, X; Sun, T; Wang, Q; Xu, Q; Zhou, J	1
Ge, J; Wang, Z	1
Ayaori, M; Iguchi, Y; Ikewaki, K; Kihara, T; Komatsu, T; Mochio, S; Momiyama, Y; Nagata, M; Nakaya, K; Sasaki, M; Sato, H; Takiguchi, S; Uto-Kondo, H; Yakushiji, E; Yogo, M	1
Ballantyne, CM; Cain, VA; Hoogeveen, RC; Karlson, BW; Palmer, MK; Raya, JL	1
Izuhara, M; Matsuda, M; Mitsuoka, H; Shioji, K; Uegaito, T	1
Abdalla, DSP; Dias, PCS; Ferreira, DQC; Paiva, MSMO; Pedrosa, LFC; Rezende, AA; Sena-Evangelista, KCM; Ururahy, MAG	1
Ara, N; Iuchi, A; Miyoshi, H; Mizuguchi, Y; Nagase, N; Oishi, Y; Oki, T	1
Bauer, I; Bertolotto, M; Dallegri, F; Fabre, M; Galan, K; Lenglet, S; Mach, F; Montecucco, F; Nencioni, A; Palombo, D; Pane, B; Pelli, G; Pende, A; Python, M; Quercioli, A; Spinella, G; Vuilleumier, N	1
Toth, PP	1
Simonyi, G	1
Elisaf, MS; Kostapanos, MS; Rizos, CV	1
Kuwano, T; Miura, S; Saku, K; Shimizu, T; Tanigawa, H; Uehara, Y; Zhang, B	1
Chen, X; Chen, Z; Li, S; Wang, X; Zhao, W	1
Liu, Y; Ren, L; Wang, P; Wang, Z; Ye, H; Zhao, N	1
Dostal, E; Gaspar, L; Goliasch, G; Hofbauer, SL; Huber, K; Kastl, SP; Katsaros, KM; Krychtiuk, KA; Maurer, G; Oravec, S; Pfaffenberger, S; Pongratz, T; Speidl, WS; Wojta, J; Wonnerth, A	1
Kapur, NK; Musunuru, K	1
Nicholls, SJ	1
Kastelein, JJ; Marck, R; Meuwese, MC; Mooij, HL; Nieuwdorp, M; Stroes, ES; van Lith, B; Vink, H	1
Nitta, K; Ogawa, T; Sawara, Y; Takei, T; Tsuchiya, K; Uchida, K; Yoshida, T	1
Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S	1
Bazzano, LA; Bucciarelli, T; D'Orazio, N; di Ilio, E; Mancini, B; Riccioni, G	1
Behrendt, M; Brandt-Eliasson, U; Forsberg, GB; Gan, LM; Grönros, J; Hansson, GI; Wikström, J	1
Kurabayashi, M; Yamazaki, T	1
Humboldt, T; Konstantinides, S; Schäfer, K; Schroeter, MR	1
Devaraj, S; Jialal, I	1
Creager, MA; Donnelly, J; Ganz, P; Liao, JK; Liu, PY; Nohria, A; Rawlings, R; Selwyn, A	1
Nasir, K; Santos, RD	1
Drexel, H; Rein, P; Saely, CH; Vonbank, A	1
Boffito, M; Collot-Teixeira, S; De Lorenzo, F; Gazzard, B; McGregor, JL; Shotliff, K; Xiao, H	1
Balog, C; Bayturan, O; Crowe, TD; Kapadia, S; Lavoie, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Uno, K; Wolski, K	1
Chi, J; Guo, H; Liu, L; Shi, Y; Sun, A; Xu, F	1
Katona, A; Márk, L	1
Barrios, V; Escobar, C	1
Cipollone, F; Fischer, JW; Marzoll, A; Melchior-Becker, A	1
Burtseva, EA; Goloviuk, AL; Ivanov, LO; Kuntsevich, GI; Pokrovskiĭ, AV; Suntsov, DS; Zotikov, AE	1
D'Orazio, N; Mancini, B; Riccioni, G; Vitulano, N; Zanasi, A	1
Bots, ML; Crouse, JR; Grobbee, DE; O'Leary, DH; Palmer, MK; Peters, SA; Raichlen, JS	1
Ballantyne, CM; Haddad, RM	1
Abel, T; Fehér, J	1
Aikawa, M; Ganz, P; Josephson, L; Kacher, DF; Libby, P; Morishige, K; Weissleder, R	1
Kones, R	1
Ballantyne, C; Barter, P; Borgman, M; Chapman, MJ; Erbel, R; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS	1
Agatston, A; Blaha, MJ; Blankstein, R; Blumenthal, RS; Budoff, MJ; Criqui, MH; Cushman, M; Lakoski, S; Nasir, K; O'Leary, DH; Rivera, JJ; Szklo, M	1
Bi, H; Chen, WA; Daugherty, A; Hong, B; Luo, Y; Wang, JA; Wang, Y; Xie, X; Zhang, S	1
Targher, G	1
Bots, ML; Crouse, JR; Dogan, S; Evans, GW; Grobbee, DE; Meijer, R; O'Leary, DH; Palmer, MK; Peters, SA; Raichlen, JS	1
Bots, ML; Crouse, JR; den Ruijter, HM; Evans, GW; Grobbee, DE; Lind, L; O'Leary, DH; Palmer, MK; Peters, SA; Raichlen, JS	1
Catapano, AL; Norata, GD; Pirillo, A	1
Bureeva, S; Hurt-Camejo, E; Kaput, J; Kleemann, R; Kooistra, T; Nikolsky, Y; Perlina, A; van Ommen, B; Verschuren, L; Wielinga, PY	1
Freedman, B; Kuan, WP; Lee, KK; Lee, VW; Li, EK; Li, M; Li, TK; Shang, Q; Tam, LS; Tomlinson, B; Tseung, L; Yip, GW; Yu, CM	1
Bots, ML; Crouse, JR; Dogan, S; Evans, GW; Grobbee, DE; O'Leary, DH; Palmer, MK; Plantinga, Y; Raichlen, JS	1
Demonte, A; Fassini, PG; Ferreira, ES; Neves, VA; Noda, RW; Silva, MA	1
de Almeida, EA; Ozaki, MR	1
Fu, X; Lu, MM; Luo, RN; Tao, LJ; Wang, R; Zhou, J	1
Schaefer, JR	1
Cao, HM; Feng, J; Li, GY; Li, J; Liu, B; Liu, M; Wang, Q	1
Bots, ML; Crouse, JR; den Ruijter, HM; Evans, GW; Grobbee, DE; Koffijberg, H; Moons, KG; O'Leary, DH; Palmer, MK; Peters, SA; Raichlen, JS	1
Bots, ML; Crouse, JR; den Ruijter, HM; Evans, GW; Grobbee, DE; O'Leary, DH; Palmer, MK; Peters, SA; Raichlen, JS	1
Cao, HM; Liu, B; Wang, HB; Wang, Q; Zhang, JY	1
Antonioli, L; Aydinoglu, F; Bernardini, N; Blandizzi, C; Colucci, R; Duranti, E; Fornai, M; Ippolito, C; Rugani, I; Segnani, C; Taddei, S; Virdis, A	1
Igase, M; Kido, T; Kohara, K; Miki, T; Nagai, T; Ochi, M; Ochi, N; Tabara, Y	1
Blumenthal, RS; Cushman, M; Greenland, P; Lakoski, S; Lloyd-Jones, DM; Mann, DM; Michos, ED; Muntner, P; Shimbo, D	1
Chi, J; Guo, H; Ji, Z; Liu, L; Lv, H; Peng, F; Tang, W; Xu, F; Zhai, X	1
Li, L; Yang, HB; Zhang, JY; Zhao, XY; Zhao, YT	1
Kelder, T; Kleemann, R; Kooistra, T; Radonjic, M; van Ommen, B; Verschuren, L; Wielinga, PY	1
Calza, L; Colangeli, V; Danese, I; Magistrelli, E; Manfredi, R; Salvadori, C; Serra, C; Trapani, FF; Verucchi, G; Viale, P	1
Deng, Z; Du, R; Geng, M; Guo, Z; Liang, W; Wu, H; Yan, G; Ye, P; Zhang, H	1
DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH; Serebruany, VL	1
Chen, J; Li, D; Mehta, JL; Schaefer, R	1
Ivleva, AIa	1
Ferdinand, KC	1
Bots, AF; Kastelein, JJ	1
Schachter, M; Wierzbicki, AS	1
Rozenman, Y	1
Port, SC	1
Hartmann, M; von Birgelen, C	1
Daida, H; Hiro, T; Matsuzaki, M; Saito, S; Takayama, T; Yamagishi, M; Yamaguchi, T	1
Bellosta, S; Camera, M; Canavesi, M; Corsini, A; Monetti, M; Paoletti, R; Parente, R; Tremoli, E	1
Bots, ML; Crouse, JR; Evans, GW; Grobbee, DE; O'Leary, DH; Palmer, MK; Raichlen, JS; Riley, WA	1
Balligand, JL; Davey, PC; De Keyzer, D; Desjardins, F; Geeraert, B; Herregods, MC; Holvoet, P; Mertens, A; Smith, G; Verreth, W	1
Mikhailidis, DP; Paraskevas, KI; Wierzbicki, AS	1
Davidson, MH	1
García-Moll, X	1
Enomoto, S; Fukuda, D; Nagai, R; Nakamura, K; Sata, M	1
Crouse, JR	1
Orr, JD	1
Keating, GM; Robinson, DM	1

Reviews

20 review(s) available for fluorobenzenes and Atherogenesis

Article	Year
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER. Atherosclerosis, 2013, Volume: 228, Issue:1 Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2013
Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin. Clinical interventions in aging, 2014, Volume: 9 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Atherosclerosis; China; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult	2014
An update on the benefits and risks of rosuvastatin therapy. Postgraduate medicine, 2014, Volume: 126, Issue:2 Topics: Atherosclerosis; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. Drug safety, 2014, Volume: 37, Issue:7 Topics: Atherosclerosis; Cholesterol, LDL; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides	2014
Clinical efficacy and safety of statins in managing cardiovascular risk. Vascular health and risk management, 2008, Volume: 4, Issue:2 Topics: Atherosclerosis; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Muscular Diseases; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2008
Rosuvastatin and progression of atherosclerosis. Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:7 Topics: Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Coronary Vessels; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2008
[Pleiotropic effects of statins]. Revista medica de Chile, 2008, Volume: 136, Issue:6 Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2008
Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis? Atherosclerosis, 2009, Volume: 205, Issue:2 Topics: Adult; Aged; Atherosclerosis; Carotid Arteries; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Models, Anatomic; Pyrimidines; Radionuclide Imaging; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Tunica Intima; Tunica Media	2009
[From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice]. Orvosi hetilap, 2009, Nov-01, Volume: 150, Issue:44 Topics: Aged; Atherosclerosis; Attitude of Health Personnel; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Prescriptions; Family Practice; Female; Fluorobenzenes; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Expectancy; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2009
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:11 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2009
[Role of rosuvastatin in current lipid-lowering therapy]. Orvosi hetilap, 2010, Aug-29, Volume: 151, Issue:35 Topics: Acute Coronary Syndrome; Atherosclerosis; C-Reactive Protein; Cholesterol; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2010
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug design, development and therapy, 2010, Dec-09, Volume: 4 Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2010
[HDL level or HDL function as the primary target in preventive cardiology]. Herz, 2012, Volume: 37, Issue:1 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation	2012
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgraduate medicine, 2013, Volume: 125, Issue:1 Topics: Atherosclerosis; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides	2013
[Efficacy of lipid correcting therapy with the use of rosuvastatin]. Kardiologiia, 2005, Volume: 45, Issue:6 Topics: Atherosclerosis; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2005
Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:11 Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Interactions; Drug Labeling; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Product Surveillance, Postmarketing; Pyrimidines; Randomized Controlled Trials as Topic; Rhabdomyolysis; Risk Assessment; Rosuvastatin Calcium; Sulfonamides	2005
Rosuvastatin in elderly patients. Drugs & aging, 2007, Volume: 24, Issue:11 Topics: Aged; Atherosclerosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2007
An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. Expert opinion on drug metabolism & toxicology, 2008, Volume: 4, Issue:3 Topics: Absorption; Atherosclerosis; Cholesterol, LDL; Cytochrome P-450 CYP3A; Drug Interactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2008
Statins in the spectrum of neurologic disease. Current atherosclerosis reports, 2008, Volume: 10, Issue:1 Topics: Alzheimer Disease; Animals; Atherosclerosis; Cardiovascular Diseases; Diabetic Neuropathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Multiple Sclerosis; Nervous System Diseases; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pyrimidines; Reactive Oxygen Species; Rosuvastatin Calcium; Stroke; Sulfonamides	2008
Rosuvastatin: a review of its effect on atherosclerosis. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2008, Volume: 8, Issue:2 Topics: Atherosclerosis; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2008

Trials

32 trial(s) available for fluorobenzenes and Atherogenesis

Article	Year
Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study. Stroke, 2022, Volume: 53, Issue:10 Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Fluorobenzenes; Humans; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2022
Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis-design, rationale, and methodology of the METEOR-China study. Trials, 2020, Nov-11, Volume: 21, Issue:1 Topics: Atherosclerosis; Carotid Intima-Media Thickness; China; Fluorobenzenes; Humans; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2020
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International heart journal, 2013, Volume: 54, Issue:1 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Japan; Lipid Metabolism; Male; Middle Aged; Outcome Assessment, Health Care; Pharmacovigilance; Pravastatin; Preventive Health Services; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2013
Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study. Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:6 Topics: Aged; Atherosclerosis; Carotid Intima-Media Thickness; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors	2013
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. European journal of clinical investigation, 2013, Volume: 43, Issue:7 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Pilot Projects; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors	2013
Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study. Atherosclerosis, 2014, Volume: 232, Issue:1 Topics: Aged; Anthropometry; Aorta; Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Endothelium, Vascular; Female; Fluorobenzenes; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis, 2014, Volume: 232, Issue:1 Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome	2014
Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin. Cardiovascular therapeutics, 2014, Volume: 32, Issue:3 Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Dyslipidemias; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Societies, Medical; Sulfonamides; Time Factors; Treatment Outcome	2014
The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2014, Volume: 28, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anthropometry; Atherosclerosis; Biomarkers; Dietary Supplements; Female; Fluorobenzenes; Gene Expression Regulation; Humans; Male; Metallothionein; Middle Aged; Molecular Sequence Data; Placebos; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Zinc	2014
Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study. International heart journal, 2014, Volume: 55, Issue:2 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
Influence of comorbid cardiovascular risk factors on left atrial-left ventricular interaction in asymptomatic patients: clinical application of two-dimensional speckle-tracking echocardiography. International heart journal, 2014, Volume: 55, Issue:2 Topics: Aged; Atherosclerosis; Atrial Function, Left; Carotid Intima-Media Thickness; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Function, Left	2014
Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:17 Topics: Aged; Atherosclerosis; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tunica Intima	2008
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. Journal of atherosclerosis and thrombosis, 2008, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2008
Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. The American journal of cardiology, 2009, Feb-15, Volume: 103, Issue:4 Topics: Aged; Atherosclerosis; Atorvastatin; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Regional Blood Flow; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides; White People	2009
Prevention of atherosclerosis in patients living with HIV. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Atherosclerosis; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Disease Progression; Double-Blind Method; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome	2009
Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials. JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:7 Topics: Aged; Atherosclerosis; Calcinosis; Disease Progression; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional	2009
One-year treatment with rosuvastatin reduces intima-media thickness in 45 hypercholesterolemic subjects with asymptomatic carotid artery disease. Pharmacology, 2010, Volume: 85, Issue:2 Topics: Atherosclerosis; Carotid Artery Diseases; Cross-Sectional Studies; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tunica Intima; Tunica Media	2010
C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of internal medicine, 2010, Volume: 268, Issue:2 Topics: Aged; Atherosclerosis; Biomarkers; C-Reactive Protein; Carotid Arteries; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tunica Intima; Tunica Media	2010
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Current medical research and opinion, 2011, Volume: 27, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography	2011
The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:9 Topics: Aged; Atherosclerosis; Carotid Arteries; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyrimidines; Reproducibility of Results; Rosuvastatin Calcium; Sulfonamides; Ultrasonography	2011
Manual or semi-automated edge detection of the maximal far wall common carotid intima-media thickness: a direct comparison. Journal of internal medicine, 2012, Volume: 271, Issue:3 Topics: Adult; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Disease Progression; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Reproducibility of Results; Risk; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tunica Intima; Tunica Media	2012
Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scandinavian journal of rheumatology, 2011, Volume: 40, Issue:6 Topics: Apolipoproteins B; Arthritis, Rheumatoid; Atherosclerosis; Carotid Intima-Media Thickness; Carotid Stenosis; Cholesterol; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Treatment Outcome; Vascular Stiffness	2011
Algorithms to measure carotid intima-media thickness in trials: a comparison of reproducibility, rate of progression and treatment effect. Journal of hypertension, 2011, Volume: 29, Issue:11 Topics: Aged; Algorithms; Atherosclerosis; Cardiology; Carotid Arteries; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyrimidines; Reproducibility of Results; Risk; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media	2011
Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis. The Journal of international medical research, 2011, Volume: 39, Issue:6 Topics: Atherosclerosis; Atorvastatin; C-Reactive Protein; Endothelium, Vascular; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Phosphorylation; Protein Subunits; Pyrimidines; Pyrroles; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides; Vasodilation	2011
Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:10 Topics: Aged; Asian People; Atherosclerosis; Brachial Artery; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; rho-Associated Kinases; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Vasodilation	2012
Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause (New York, N.Y.), 2012, Volume: 19, Issue:12 Topics: Aged; Atherosclerosis; Biomarkers; Brachial Artery; C-Reactive Protein; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vascular Stiffness	2012
C-reactive protein level and the incidence of eligibility for statin therapy: the multi-ethnic study of atherosclerosis. Clinical cardiology, 2013, Volume: 36, Issue:1 Topics: Aged; Aged, 80 and over; Atherosclerosis; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; Ethnicity; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States	2013
[Effects of domestic rosuvastatin on coronary plaque in patients with mild-to-moderate coronary artery stenosis as evaluated by virtual histology-intravascular ultrasound]. Zhonghua yi xue za zhi, 2012, Jun-12, Volume: 92, Issue:22 Topics: Aged; Atherosclerosis; Coronary Stenosis; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography	2012
Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS research and human retroviruses, 2013, Volume: 29, Issue:3 Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; Young Adult	2013
Achieving lipid goals in real life: the Dutch DISCOVERY study. International journal of clinical practice, 2005, Volume: 59, Issue:12 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides	2005
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultras Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:2 Topics: Adult; Aged; Atherosclerosis; Coronary Artery Disease; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional	2007
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA, 2007, Mar-28, Volume: 297, Issue:12 Topics: Aged; Atherosclerosis; Carotid Arteries; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Tunica Intima; Ultrasonography	2007

Other Studies

46 other study(ies) available for fluorobenzenes and Atherogenesis

Article	Year
Analytical study for the charge-transfer complexes of rosuvastatin calcium with π-acceptors. Molecules (Basel, Switzerland), 2013, Jul-03, Volume: 18, Issue:7 Topics: Anticholesteremic Agents; Atherosclerosis; Chemistry, Pharmaceutical; Cholesterol; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Spectrophotometry; Sulfonamides	2013
Effects of rosuvastatin on the production and activation of matrix metalloproteinase-2 and migration of cultured rat vascular smooth muscle cells induced by homocysteine. Journal of Zhejiang University. Science. B, 2013, Volume: 14, Issue:8 Topics: Animals; Atherosclerosis; Cell Movement; Cells, Cultured; Enzyme Activation; Fluorobenzenes; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Myocytes, Smooth Muscle; Pyrimidines; Rats; Rosuvastatin Calcium; Sulfonamides; Tissue Inhibitor of Metalloproteinase-2	2013
Erythrocyte membrane cholesterol and lipid core growth in a rabbit model of atherosclerosis: modulatory effects of rosuvastatin. International journal of cardiology, 2013, Dec-10, Volume: 170, Issue:2 Topics: Animals; Atherosclerosis; Cholesterol; Diet, Atherogenic; Disease Models, Animal; Erythrocyte Membrane; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides	2013
Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I. European journal of pharmacology, 2014, Jan-15, Volume: 723 Topics: Angiotensin II; Animals; Aorta; Atherosclerosis; Cholesterol; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pyrimidines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; RNA, Messenger; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Triglycerides; Up-Regulation	2014
Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis. Mediators of inflammation, 2014, Volume: 2014 Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Stenosis; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Neutrophil Activation; Neutrophils; NF-kappa B; Osteopontin; Osteoprotegerin; Pyrimidines; Pyrroles; RANK Ligand; Risk Factors; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2014
[Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial]. Orvosi hetilap, 2014, Apr-27, Volume: 155, Issue:17 Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Databases, Factual; Drug Prescriptions; Drug Therapy, Combination; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Health; Male; Middle Aged; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires; Treatment Outcome	2014
Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:10 Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; Biological Transport; Cell Line; Cholesterol Esters; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors	2014
Protective effect of co-administration of rosuvastatin and probucol on atherosclerosis in rats. Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:10 Topics: Animals; Antioxidants; Atherosclerosis; Drug Therapy, Combination; Fluorobenzenes; Lipids; Male; Oxidative Stress; Platelet Endothelial Cell Adhesion Molecule-1; Probucol; Pyrimidines; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Tunica Intima	2014
[Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients]. Zhonghua yi xue za zhi, 2014, Aug-19, Volume: 94, Issue:31 Topics: Ankle Brachial Index; Ankle Joint; Atherosclerosis; Blood Flow Velocity; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Pulsatile Flow; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vascular Stiffness	2014
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis, 2014, Volume: 237, Issue:2 Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Fluorobenzenes; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Inflammation; Interleukin-10; Lipids; Lipoproteins, HDL; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Monocytes; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2014
Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. Journal of lipid research, 2009, Volume: 50, Issue:1 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Dextrans; Endothelium; Fluorobenzenes; Glycocalyx; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Permeability; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2009
Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:14 Topics: Aged; Atherosclerosis; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Tunica Intima	2008
Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis. American journal of physiology. Heart and circulatory physiology, 2008, Volume: 295, Issue:5 Topics: Animals; Apolipoproteins E; Atherosclerosis; Biomarkers; Blood Flow Velocity; Brachiocephalic Trunk; Coronary Circulation; Coronary Vessels; Disease Models, Animal; Disease Progression; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrimidines; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Time Factors; Ultrasonography	2008
Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. Atherosclerosis, 2009, Volume: 205, Issue:1 Topics: Animals; Apolipoproteins E; Atherosclerosis; beta-Galactosidase; Bone Marrow Cells; Chemokine CXCL12; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyrimidines; Rosuvastatin Calcium; Signal Transduction; Stem Cells; Sulfonamides	2009
Jupiter to Earth: CRP promotes atherothrombosis. Metabolic syndrome and related disorders, 2009, Volume: 7, Issue:1 Topics: Aged; Animals; Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Multicenter Studies as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2009
Serum levels of C-reactive protein in patients with stable coronary artery disease: JUPITER in perspective. International journal of cardiology, 2010, Oct-29, Volume: 144, Issue:3 Topics: Aged; Atherosclerosis; Biomarkers; C-Reactive Protein; Cohort Studies; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides	2010
Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Archives of medical research, 2009, Volume: 40, Issue:5 Topics: Animals; Arteries; Atherosclerosis; Cholesterol; Fluorobenzenes; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Pyrimidines; Receptors, LDL; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2009
Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment? Journal of cellular and molecular medicine, 2011, Volume: 15, Issue:2 Topics: Animals; Apolipoproteins E; Atherosclerosis; Biglycan; Cell Line; Collagen; Decorin; Endarterectomy, Carotid; Extracellular Matrix Proteins; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leucine; Lipoproteins, LDL; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; Proteoglycans; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
[Rosuvastatin in prevention of cardiac complications following surgical treatment of patients with vascular pathology]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2009, Volume: 15, Issue:3 Topics: Adult; Aged; Aorta, Abdominal; Atherosclerosis; Brachiocephalic Trunk; Dose-Response Relationship, Drug; Embolism, Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Postoperative Complications; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vascular Surgical Procedures	2009
METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis. The Physician and sportsmedicine, 2010, Volume: 38, Issue:2 Topics: Atherosclerosis; Carotid Arteries; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Sulfonamides; Tunica Intima	2010
High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation, 2010, Oct-26, Volume: 122, Issue:17 Topics: Animals; Aorta, Abdominal; Atherosclerosis; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Ferrosoferric Oxide; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Magnetic Resonance Imaging; Male; Metal Nanoparticles; Nanoparticles; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2010
Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:6 Topics: Adult; Aged; Atherosclerosis; Body Mass Index; C-Reactive Protein; Calcium; Cardiovascular Diseases; Carotid Arteries; Clinical Trials as Topic; Cross-Sectional Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Obesity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tunica Intima; Tunica Media; Waist Circumference	2011
Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms. Atherosclerosis, 2011, Volume: 217, Issue:1 Topics: Angiotensin II; Animal Feed; Animals; Anti-Inflammatory Agents; Aorta; Aortic Aneurysm, Abdominal; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2011
High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study. Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:6 Topics: Aged; Aged, 80 and over; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches. Current opinion in lipidology, 2011, Volume: 22, Issue:4 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis. BMC systems biology, 2011, Aug-12, Volume: 5 Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cardiovascular Agents; Drug Design; Fenofibrate; Fluorobenzenes; Gene Expression Regulation; Humans; Hydrocarbons, Fluorinated; Mice; Microarray Analysis; Models, Biological; Pyrimidines; Regulatory Elements, Transcriptional; Rosuvastatin Calcium; Structure-Activity Relationship; Sulfonamides; Systems Biology	2011
Soybean glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic rats. Lipids in health and disease, 2011, Sep-21, Volume: 10 Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholic Acid; Combined Modality Therapy; Dietary Supplements; Fluorobenzenes; Food-Drug Interactions; Globulins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Liver; Male; Pyrimidines; Rats; Rats, Wistar; Risk Factors; Rosuvastatin Calcium; Soybean Proteins; Sulfonamides; Triglycerides	2011
Evolution and involution of atherosclerosis and its relationship with vascular reactivity in hypercholesterolemic rabbits. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2013, Volume: 65, Issue:3 Topics: Animals; Aorta, Thoracic; Atherosclerosis; Cholesterol, Dietary; Data Interpretation, Statistical; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipids; Male; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides; Time Factors; Vasodilation	2013
[Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice]. Zhonghua xin xue guan bing za zhi, 2011, Volume: 39, Issue:8 Topics: Animals; Antigens, Differentiation; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Fluorobenzenes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta	2011
Multiple imputation of missing repeated outcome measurements did not add to linear mixed-effects models. Journal of clinical epidemiology, 2012, Volume: 65, Issue:6 Topics: Algorithms; Atherosclerosis; Biometry; Carotid Intima-Media Thickness; Clinical Trials as Topic; Confidence Intervals; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Male; Middle Aged; Models, Statistical; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides	2012
Biologically implausible carotid intima-media thickness measurement values: effects on rate of change over time. Current medical research and opinion, 2012, Volume: 28, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Humans; Male; Middle Aged; Placebos; Predictive Value of Tests; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tunica Intima	2012
Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. British journal of pharmacology, 2013, Volume: 169, Issue:3 Topics: Angiotensin II; Animals; Atherosclerosis; Cyclooxygenase 1; Disease Models, Animal; Endothelium, Vascular; Enzyme Induction; Enzyme Inhibitors; Extracellular Matrix; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mechanical Phenomena; Membrane Proteins; Mesenteric Arteries; NADPH Oxidase 4; NADPH Oxidases; Phosphorylation; Protein Processing, Post-Translational; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides; Vascular Resistance; Vasodilation	2013
Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterol-lowering effect in insulin-resistant mice. Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:5 Topics: Animals; Atherosclerosis; Diet; Fluorobenzenes; Fructose; Glucose Transporter Type 4; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipids; Liver; Male; Mice; Mice, Knockout; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptors, LDL; Rosuvastatin Calcium; Sulfonamides	2012
Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy. Pharmacogenetics and genomics, 2012, Volume: 22, Issue:12 Topics: Animals; Anticholesteremic Agents; Apolipoprotein E3; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Mice; Mice, Transgenic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Systems Biology	2012
[Effect of intensive rosuvastatin therapy on adhesion molecules and the upstream mechanism in patients with peripheral atherosclerosis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2012, Volume: 32, Issue:11 Topics: Atherosclerosis; Cell Adhesion Molecules; Female; Fluorobenzenes; Humans; Intercellular Adhesion Molecule-1; Male; Middle Aged; Monocytes; PPAR gamma; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vascular Cell Adhesion Molecule-1	2012
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis, 2006, Volume: 184, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Phosphorylation; Pyrimidines; Renin-Angiotensin System; Rosuvastatin Calcium; Scavenger Receptors, Class E; Sulfonamides; Tetrazoles	2006
Spinning stars: ASTEROID's impact on atherosclerosis. Lancet (London, England), 2006, May-20, Volume: 367, Issue:9523 Topics: Advertising; Atherosclerosis; Clinical Trials as Topic; Drug Industry; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2006
High-dose statins and atherosclerosis regression. JAMA, 2006, Oct-18, Volume: 296, Issue:15 Topics: Atherosclerosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional	2006
High-dose statins and atherosclerosis regression. JAMA, 2006, Oct-18, Volume: 296, Issue:15 Topics: Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2006
High-dose statins and atherosclerosis regression. JAMA, 2006, Oct-18, Volume: 296, Issue:15 Topics: Atherosclerosis; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional	2006
I've just been diagnosed with atherosclerosis. Is there anything I can do to unclog my arteries? The Johns Hopkins medical letter health after 50, 2006, Volume: 18, Issue:7 Topics: Atherosclerosis; Diet, Fat-Restricted; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2006
Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacological research, 2007, Volume: 55, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Valve; Apolipoproteins E; Atherosclerosis; Cardiovascular Agents; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Intercellular Adhesion Molecule-1; Macrophages; Mice; Mice, Knockout; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thromboplastin; Time Factors; Vascular Cell Adhesion Molecule-1	2007
Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. British journal of pharmacology, 2007, Volume: 151, Issue:3 Topics: Animals; Aorta; Atherosclerosis; Blood Glucose; Body Weight; Cell Line; Dyslipidemias; Fluorobenzenes; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Leptin; Lipids; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; PPAR gamma; Pyrimidines; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides; Superoxide Dismutase	2007
METEOR: aiming at the stars for asymptomatic carotid artery atherosclerosis? International journal of clinical practice, 2007, Volume: 61, Issue:8 Topics: Atherosclerosis; Carotid Artery Diseases; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2007
[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?]. Revista espanola de cardiologia, 2007, Volume: 60, Issue:12 Topics: Acute Coronary Syndrome; Atherosclerosis; Biometry; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Inflammation; Metformin; Oxidative Stress; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha	2007
Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2009, Volume: 63, Issue:1 Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Death; Cells, Cultured; Endothelial Cells; Female; Fluorobenzenes; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2009